First human trial launches for experimental cancer drug PRL3-ZUMAB

NCT ID NCT03191682

Ongoing Disease control Sponsor: National University Hospital, Singapore Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests the safety of a new drug called PRL3-ZUMAB in people with advanced solid tumors that have not responded to standard treatments. It is the first time this drug is given to humans, after showing promise in animal tests. The trial will enroll 38 participants and gradually increase the dose to find the safest level.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PRL3-ZUMAB
What this could lead to: If it works, this could point toward a new treatment option for advanced solid tumors that have not responded to standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 38 participants, so it is primarily testing safety, not effectiveness. The drug may not work or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia neoplasm plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

National University Hospital

Singapore, Singapore, 119.074, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.